Meher Burki, MD
Hematology & Oncology · West Chester, PANPI 1184877813
Payments from drug & device makers
Across 18 payments — averaging $213.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CTI Biopharma Corp.$2K
- AstraZeneca$1K
- Daiichi Sankyo Inc.$550
- Servier Pharmaceuticals LLC$319
- Pharmacyclics LLC, An Abbvie Company$164
- Gilead$12
- plus $1 from 1 others
What the payments were for
- Consulting fees$1,08028%
- Speaking & faculty fees$2,27559%
- Food & beverage$642%
- Education$43111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CTI Biopharma Corp. | 1 | $1,725 |
| AstraZeneca | 2 | $1,080 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Servier Pharmaceuticals LLC | 8 | $319 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $164 |
| Gilead | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,850 in reported general payments places this provider in the 50th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 12 | $280,767 |
| IbrancePalbociclib | 12 | $184,932 |
| EliquisApixaban | 64 | $58,172 |
| XareltoRivaroxaban | 45 | $54,132 |
| Anastrozole | 317 | $8,915 |
| Letrozole | 68 | $1,628 |
| Hydroxyurea | 26 | $1,014 |
| Tamoxifen Citrate | 46 | $730 |
| Alendronate Sodium | 105 | $676 |
| Ondansetron Hcl | 70 | $585 |
| Prochlorperazine Maleate | 51 | $458 |
| Dexamethasone | 14 | $428 |
| Warfarin Sodium | 30 | $274 |
| Gabapentin | 31 | $226 |
| Oxycodone Hcl | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in West Chester
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.